NASDAQ:EMBC Embecta (EMBC) Stock Forecast, Price & News $26.90 -0.32 (-1.18%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$26.62▼$27.8250-Day Range$26.85▼$31.0752-Week Range$22.30▼$36.64Volume288,500 shsAverage Volume639,314 shsMarket Capitalization$1.54 billionP/E Ratio16.60Dividend Yield2.23%Price Target$26.50 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Embecta MarketRank™ ForecastAnalyst RatingReduce1.33 Rating ScoreUpside/Downside1.5% Downside$26.50 Price TargetShort InterestBearish5.74% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainabilityN/ANews Sentiment0.38Based on 9 Articles This WeekInsider TradingN/AProj. Earnings Growth-10.38%From $2.60 to $2.33 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.39 out of 5 starsMedical Sector954th out of 1,010 stocksSurgical & Medical Instruments Industry95th out of 104 stocks 0.7 Analyst's Opinion Consensus RatingEmbecta has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no buy ratings, 1 hold rating, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.50, Embecta has a forecasted downside of 1.5% from its current price of $26.90.Amount of Analyst CoverageEmbecta has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.74% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Embecta has recently decreased by 2.98%, indicating that investor sentiment is improving. Previous Next 2.5 Dividend Strength Dividend YieldEmbecta pays a meaningful dividend of 2.23%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 37.04%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 25.75% next year. This indicates that Embecta will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EMBC. Previous Next 1.9 News and Social Media Coverage News SentimentEmbecta has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Embecta this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for EMBC on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.22% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.45% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Embecta are expected to decrease by -10.38% in the coming year, from $2.60 to $2.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 16.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 16.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 98.68. Previous Next See Top Rated MarketRank™ Stocks Here About Embecta (NASDAQ:EMBC) StockEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.Read More Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address EMBC Stock News HeadlinesMay 28, 2023 | americanbankingnews.comEmbecta (NASDAQ:EMBC) Releases FY 2023 Earnings GuidanceMay 26, 2023 | americanbankingnews.comEmbecta (EMBC) vs. The Competition Head to Head ContrastMay 29, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 24, 2023 | americanbankingnews.comEmbecta Corp. Declares Quarterly Dividend of $0.15 (NASDAQ:EMBC)May 24, 2023 | americanbankingnews.comEmbecta Corp. Announces Quarterly Dividend of $0.15 (NASDAQ:EMBC)May 23, 2023 | americanbankingnews.comCritical Contrast: Embecta (EMBC) and Its RivalsMay 23, 2023 | americanbankingnews.comEmbecta (EMBC) and The Competition Financial AnalysisMay 20, 2023 | finance.yahoo.comJust Four Days Till Embecta Corp. (NASDAQ:EMBC) Will Be Trading Ex-DividendMay 29, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 15, 2023 | finance.yahoo.comembecta to Participate in Investor ConferencesMay 15, 2023 | finance.yahoo.comUPDATE -- embecta to Participate in Investor ConferencesMay 15, 2023 | markets.businessinsider.comMorgan Stanley Maintains Underweight Rating for Embecta: Here's What You Need To KnowMay 15, 2023 | finance.yahoo.comEmbecta Corp. (EMBC) Recently Broke Out Above the 50-Day Moving AverageMay 15, 2023 | finance.yahoo.comEmbecta Corp. (EMBC) Crossed Above the 200-Day Moving Average: What That Means for InvestorsMay 14, 2023 | msn.comEmbecta (EMBC) Declares $0.15 DividendMay 13, 2023 | finance.yahoo.comEmbecta Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2023 | marketwatch.com8-K: Embecta Corp.May 12, 2023 | marketwatch.comembecta and Tidepool partner to develop automated insulin delivery system for people with Type 2 diabetesMay 12, 2023 | markets.businessinsider.comBTIG Keeps Their Hold Rating on Embecta Corporation (EMBC)May 12, 2023 | seekingalpha.comEmbecta Corp. (EMBC) Q2 2023 Earnings Call TranscriptMay 12, 2023 | msn.comEmbecta: Q2 Earnings InsightsMay 12, 2023 | finance.yahoo.comembecta and Tidepool partner to develop automated insulin delivery system for people with Type 2 diabetesMay 12, 2023 | finance.yahoo.comEmbecta Corp. Reports Second Quarter Fiscal 2023 Financial ResultsMay 10, 2023 | americanbankingnews.comEmbecta (EMBC) Set to Announce Quarterly Earnings on FridayMay 5, 2023 | seekingalpha.comEmbecta: Capital Productivity, Incremental Profit Growth Key ChallengesMay 3, 2023 | americanbankingnews.comEmbecta Corp. (NASDAQ:EMBC) Short Interest UpdateApril 26, 2023 | finance.yahoo.comEmbecta Corp. (EMBC) Dips More Than Broader Markets: What You Should KnowSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address EMBC Company Calendar Ex-Dividend for 6/13 Dividend5/25/2023Ex-Dividend for 6/13 Dividend5/25/2023Today5/29/2023Dividend Payable6/13/2023Dividend Payable6/13/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EMBC CUSIPN/A CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees2,029Year FoundedN/APrice Target and Rating Average Stock Price Forecast$26.50 High Stock Price Forecast$28.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside-1.5%Consensus RatingReduce Rating Score (0-4)1.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.62 Trailing P/E Ratio16.60 Forward P/E Ratio10.35 P/E GrowthN/ANet Income$223.60 million Net Margins8.44% Pretax Margin11.33% Return on Equity-23.46% Return on Assets17.55% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio1.67 Sales & Book Value Annual Sales$1.13 billion Price / Sales1.36 Cash Flow$5.49 per share Price / Cash Flow4.90 Book Value($15.41) per share Price / Book-1.75Miscellaneous Outstanding Shares57,290,000Free Float57,168,000Market Cap$1.54 billion OptionableOptionable BetaN/A Key ExecutivesMr. Devdatt Kurdikar (Age 53)Pres, CEO & Director Comp: $1.19MMr. Jacob P. Elguicze (Age 49)Sr. VP & CFO Comp: $519.14kMr. Jeffrey Z. Mann (Age 49)Sr. VP, Gen. Counsel, Head of Corp. Devel. & Corp. Sec. Comp: $294.04kMr. Ajay Kumar (Age 51)Sr. VP & Chief HR Officer Comp: $616.87kMr. Shaun Curtis (Age 52)Sr. VP of Global Manufacturing & Supply Chain Comp: $501.99kMr. Brian R. Capone (Age 47)VP, Chief Accounting Officer & Corp. Controller Ms. Colleen Riley (Age 57)Sr. VP & Chief Technology Officer Ms. Ginny BlockiSr. VP of Global Marketing & Product ManagementMr. Tom Blount (Age 48)Sr. VP & Pres of North America Mr. Slobodan Radumilo (Age 51)Sr. VP & Pres of International More ExecutivesKey CompetitorsTreace Medical ConceptsNASDAQ:TMCIAlphatecNASDAQ:ATECPROCEPT BioRoboticsNASDAQ:PRCTParagon 28NYSE:FNATandem Diabetes CareNASDAQ:TNDMView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 834 shares on 5/26/2023Ownership: 0.015%Royce & Associates LPBought 57,814 shares on 5/23/2023Ownership: 0.169%Ameriprise Financial Inc.Sold 9,587 shares on 5/22/2023Ownership: 0.391%JPMorgan Chase & Co.Sold 128,319 shares on 5/18/2023Ownership: 0.161%New York State Common Retirement FundSold 21,028 shares on 5/18/2023Ownership: 0.071%View All Insider TransactionsView All Institutional Transactions EMBC Stock - Frequently Asked Questions Should I buy or sell Embecta stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Embecta in the last year. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "sell" EMBC shares. View EMBC analyst ratings or view top-rated stocks. What is Embecta's stock price forecast for 2023? 3 equities research analysts have issued 1 year price objectives for Embecta's shares. Their EMBC share price forecasts range from $25.00 to $28.00. On average, they predict the company's stock price to reach $26.50 in the next twelve months. This suggests that the stock has a possible downside of 1.5%. View analysts price targets for EMBC or view top-rated stocks among Wall Street analysts. How have EMBC shares performed in 2023? Embecta's stock was trading at $25.29 on January 1st, 2023. Since then, EMBC stock has increased by 6.4% and is now trading at $26.90. View the best growth stocks for 2023 here. How often does Embecta pay dividends? What is the dividend yield for Embecta? Embecta announced a quarterly dividend on Friday, May 12th. Shareholders of record on Monday, May 29th will be paid a dividend of $0.15 per share on Tuesday, June 13th. This represents a $0.60 annualized dividend and a yield of 2.23%. The ex-dividend date of this dividend is Thursday, May 25th. Read our dividend analysis for EMBC. What ETFs hold Embecta's stock? ETFs with the largest weight of Embecta (NASDAQ:EMBC) stock in their portfolio include First Trust Small Cap US Equity Select ETF (RNSC), Invesco S&P Spin-Off ETF (CSD), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows 100 ETF (CALF), SPDR S&P Health Care Equipment ETF (XHE), Royce Quant Small-Cap Quality Value ETF (SQLV), Adaptive Growth Opportunities ETF (AGOX) and Syntax Stratified SmallCap ETF (SSLY). Is Embecta a good dividend stock? Embecta (NASDAQ:EMBC) pays an annual dividend of $0.60 per share and currently has a dividend yield of 2.23%. The dividend payout ratio is 37.04%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EMBC will have a dividend payout ratio of 25.75% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for EMBC. What guidance has Embecta issued on next quarter's earnings? Embecta updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of $2.50-$2.60 for the period, compared to the consensus earnings per share estimate of $2.09. The company issued revenue guidance of $1.10 billion-$1.11 billion, compared to the consensus revenue estimate of $1.10 billion. What is Embecta's stock symbol? Embecta trades on the NASDAQ under the ticker symbol "EMBC." Who are Embecta's major shareholders? Embecta's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.67%), American Century Companies Inc. (8.08%), FMR LLC (7.88%), Yacktman Asset Management LP (4.53%), State Street Corp (3.96%) and Geode Capital Management LLC (1.96%). View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Embecta's stock price today? One share of EMBC stock can currently be purchased for approximately $26.90. How much money does Embecta make? Embecta (NASDAQ:EMBC) has a market capitalization of $1.54 billion and generates $1.13 billion in revenue each year. The company earns $223.60 million in net income (profit) each year or $1.62 on an earnings per share basis. How many employees does Embecta have? The company employs 2,029 workers across the globe. How can I contact Embecta? The official website for the company is www.embecta.com. The company can be reached via phone at 201-847-6880 or via email at investor.relations@embecta.com. This page (NASDAQ:EMBC) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.